Satellos Bioscience Inc.

News & Events

Press Releases

In The Media

1. Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy

   Business Wire MAY 22, 2025 7:00 AM EDT
   Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (...
   READ ARTICLE

2. Bloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrants

   Newsfile MAY 20, 2025 7:01 PM EDT
   Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Bloom Burton & Co. Inc. (Bloom Burton) an...
   READ ARTICLE

3. Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress

   Business Wire MAY 13, 2025 7:00 AM EDT
   - Completed enrollment in the Phase 1b trial in adult patients with Duchenne muscular dystrop...
   READ ARTICLE

4. Satellos to Present at the CureDuchenne FUTURES National Conference

   Business Wire MAY 7, 2025 7:00 AM EDT
   Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the ...
   READ ARTICLE

5. Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference

   Business Wire APR 29, 2025 9:04 AM EDT
   Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the ...
   READ ARTICLE

6. Satellos to Participate in Two April Investor Conferences

   Business Wire APR 2, 2025 7:00 AM EDT
   Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the ...
   READ ARTICLE

7. Satellos Reports 2024 Financial Results and Highlights Company Progress

   Business Wire MAR 26, 2025 7:00 AM EDT
   – Completed enrollment and dosing in a Phase 1a clinical trial in 72 healthy volunteer...
   READ ARTICLE

8. Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

   Business Wire MAR 19, 2025 9:00 AM EDT
   - Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after bot...
   READ ARTICLE

9. Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

   Business Wire FEB 18, 2025 8:15 AM EST
   - Satellos plans to highlight Phase 1 safety and PK data for SAT-3247 Satel...
   READ ARTICLE

10. Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers

    Business Wire FEB 10, 2025 7:00 AM EST
    - Company remains on track to report Phase 1a data from both the Single- and Multiple-Ascending D...
    READ ARTICLE